[Results of the treatment of growth hormone deficiency with methionine-somatotropin or recombinant somatotropin].
Sixteen children with hGH deficiency were treated for a year with methionyl-somatotropin (Somatonorm) or recombinant-somatotropin (Genotropin). The hormone was administrated subcutaneously 3 time/week, 0.45-0.6 IU/kg/week. After a year of treatment, the mean growth rate in those who received Somatonorm increased from 3.96 +/- 0.8 cm/yr to 9.08 +/- 2.7 cm/yr, and in those who received Genotropin from 3.6 +/- 0.6 cm/yr to 8.58 +/- 1.1 cm/yr with no significant difference. No adverse effects were observed, but four children that received Somatonorm developed antihGH antibodies with a very low binding capacity, of less than 0.1 mg/L. All the children that received Genotropin were negative for antihGH antibodies.
Dorantes-Alvarez
L M
LM
Departamento de Endocrinología Hospital Infantil de México Federico Gómez, México.
D000293:Adolescent; D000906:Antibodies / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000172:deficiency* / Q000276:immunology / Q000627:therapeutic use*; D019382:Human Growth Hormone; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D000906:Antibodies; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D013006:Growth Hormone
Resultados del tratamiento de la deficiencia de hormona de crecimiento con metionina-somatotropina o con somatotropina-recombinante.